Miraculins Inc. Signs Agreement With Duke University Medical Center For Prostate Cancer Diagnostic Project

Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company engaged in the discovery and development of products for select cancers, is pleased to announce an agreement with Duke University Medical Center ("DUMC") to further the development of Miraculins' prostate cancer diagnostic project. Under the terms of the agreement, Miraculins will combine its internal research expertise with the considerable research capabilities and patient network of DUMC.

Back to news